NeuroMab™ Anti-CD33 BBB Shuttle Antibody(NRZP-1022-ZP3557)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Immunogen

Recombinant hu and cyno CD33 extracellular domain (ECD, amino acids of 1-262 huCD33 and 1-257 cynoCD33) fused to a C-terminal Flag (RADYKDDDDK) expressed in a mammalian expression system.

Species Reactivity

Human; Cynomolgus Monkey

Clonality

Monoclonal

Host Species

Mouse

Isotype

IgG

Applications

WB; ELISA; FC; In Vitro; In Vivo

Relevant Diseases

Alzheimer's Disease

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

CD33

Official Name

CD33

Full Name

Sialic acid binding Ig-like lectin 3

Alternative Names

CD33; CD33 molecule

Product Pictures

FCM

Figure 1 shows an exemplary antibody competition experiment for human CD33 binding between anti-CD33 antibody 15G15 and anti-CD33 antibodies 27C6, 9C2, 33F9, 10D3, 7A1, 15G15, 23E4 and 33H4.

FCM

Figure 2 shows that anti-CD33 antibody 9C3 does not compete with anti-CD33 antibody 15G15.33 and binds an epitope different from 15G15.33.

FCM

Figure 3 shows that variants of the 9C3 antibody, 9C3.2, 9C3.3 and 9C3.4, have improved binding to huCD33.

FCM

Figure 4 shows that anti-CD33 antibodies 7A1, 9C2, 10D3 and 15G15 bind to the Ig-like V domain of huCD33.

FCM

Figure 5 shows that the anti-CD33 antibody 15G15 is able to bind the huCD33 Ig-like V domain without N-linked glycosylation.

FuncS

Figure 6 shows the internalization and in vitro potency of anti-CD33 antibodies 15G15 and 15G15.33 LD#1.

FuncS

Figure 7 shows the change in tumor volume (mm 3 ) over time after treatment with different doses of 15G15.33 and 15G15.33 Thio-LC V205C LD #1 in HL-60 xenografts.

FuncS

Figure 8 shows the change in tumor volume (mm3) over time after treatment with different doses of 15G15.33 and 15G15.33 Thio-LC V205C LD #1 in EOL-1 xenografts.